Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4314 Comments
1938 Likes
1
{用户名称}
{用户等级}
2 hours ago
{协议答案}
👍 106
Reply
2
{用户名称}
{用户等级}
5 hours ago
{协议答案}
👍 183
Reply
3
{用户名称}
{用户等级}
1 day ago
{协议答案}
👍 182
Reply
4
{用户名称}
{用户等级}
1 day ago
{协议答案}
👍 135
Reply
5
{用户名称}
{用户等级}
2 days ago
{协议答案}
👍 262
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.